Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 26,642 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: controlled-release oral alpha-lipoic acid; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: GARDASIL®9 (G9), V540B; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Anaheim, California • Hallandale, Florida • Hollywood, Florida + 1 more

Conditions: Generalized Anxiety Disorder
Interventions: SEP-363856, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Tucson, Arizona • Encino, California • Sherman Oaks, California + 13 more

Conditions: COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions: Rayaldee, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more

Conditions: Systemic Lupus Erythematosus
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more

Conditions: Moderate to Severe Ulcerative Colitis
Interventions: Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W, Induction- Placebo SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 55
States / cities: Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more

Conditions: Heavy Drinking, Alcohol Drinking, Substance Use, Drinking Behavior
Interventions: Standard Brief Intervention, Trauma-Informed and Peer-Supported Brief Intervention, Assessment only; Behavioral
Lead sponsor: Western Kentucky University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Polycystic Ovary Syndrome, Infertility
Interventions: Progestin, Clomiphene Citrate; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 13
States / cities: San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more

Conditions: Vasomotor Symptoms; Hot Flashes
Interventions: Erenumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Winston-Salem, North Carolina + 3 more

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo, Oseltamivir; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Cushing Syndrome
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more

Conditions: Anesthesia
Interventions: Brain.fm Music, Spectrally-matched Noise; Other
Lead sponsor: Brain.fm, Inc.; Industry
Eligibility: Not listed
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Pregnancy, Gestational Diabetes Mellitus, Class A2, Neonatal Hypoglycemia
Interventions: Blood sugar check every 2 hours, Blood sugar check every 4 hours; Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Falls Church, Virginia

Conditions: Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions: Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment; Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Meningococcal Disease
Interventions: Meningococcal ABCWY, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 19 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: RSV Infection
Interventions: RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 59 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Suicidal Ideation, Suicide Attempt
Interventions: Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S), Smartphone-delivered inactive Therapeutic Evaluative Conditioning; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Smoking Cessation
Interventions: Quitxt text messaging or Chat, Usual care; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 29 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Low Back Pain
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 66
States / cities: Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 57 more

Conditions: Abortion Late, Pain
Interventions: Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control; Procedure · Behavioral · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: San Diego, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 115
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more

Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more

Conditions: Heart Failure
Interventions: Spironolactone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

A Brief Intervention for Alcohol Users With Interpersonal Trauma

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Study of Erenumab (AMG 334) in Women With Hot Flashes

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Perioperative Audio for Anaesthesia

Intrapartum Glycemic Control in GDMA2

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior

Quitxt Mobile Text Messaging Cessation Research Study

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

Paracervical Block for Pain Control With Osmotic Dilator Placement

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Novel Treatment for Diastolic Heart Failure in Women